Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
AN2 Therapeutics, Inc.
Market Cap
$182.60M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$180.47M
Net Profit Margin
-6559.27%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$179.75M
Net Profit Margin
0.00%
TTM Avg
-2904.41%
3Y Avg
-1452.20%
5Y Avg
-968.14%
Market Cap
$179.26M
Net Profit Margin
3202.50%
TTM Avg
1601.25%
3Y Avg
554.42%
5Y Avg
279.00%
Market Cap
$189.11M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$190.07M
Net Profit Margin
0.00%
TTM Avg
-122.98%
3Y Avg
-61.49%
5Y Avg
-40.99%
Market Cap
$174.27M
Net Profit Margin
-3881.54%
TTM Avg
-6298.52%
3Y Avg
-6043.31%
5Y Avg
-5544.50%
Market Cap
$173.76M
Net Profit Margin
-229.20%
TTM Avg
-206.03%
3Y Avg
-659.07%
5Y Avg
-1951.89%
Market Cap
$192.49M
Net Profit Margin
-36.80%
TTM Avg
-24.29%
3Y Avg
-59.84%
5Y Avg
-44.50%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $182.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | -6559.27% | 0.00% | 0.00% | 0.00% |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.75M | 0.00% | -2904.41% | -1452.20% | -968.14% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | 3202.50% | 1601.25% | 554.42% | 279.00% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | 0.00% | 0.00% | 0.00% | 0.00% |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $190.07M | 0.00% | -122.98% | -61.49% | -40.99% |
| Yarrow Bioscience Inc (YARW)vs › | $174.27M | -3881.54% | -6298.52% | -6043.31% | -5544.50% |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | -229.20% | -206.03% | -659.07% | -1951.89% |
| RxSight, Inc. (RXST)vs › | $192.49M | -36.80% | -24.29% | -59.84% | -44.50% |
| Organogenesis Holdings Inc. (ORGO)vs › | $172.42M | -19.76% | 3.38% | 2.83% | 6.10% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
